Celiac Disease & Gluten Sensitivity: tTG-IgA, Villous Atrophy & the Complete Science Guide

What Celiac Disease Actually Is

Celiac disease is not a food allergy. It is not a sensitivity in the colloquial sense. It is a chronic, systemic autoimmune disorder driven by a precise immunological cascade that, in genetically susceptible individuals, is triggered every time they consume gluten — the storage protein complex found in wheat, barley, and rye.

The scale of the problem is larger than most clinicians appreciate. Approximately 1% of the global population has celiac disease, and that figure is increasing — not merely because diagnostic awareness has improved, but because cumulative gluten exposure, changes in wheat processing, and gut microbiome disruption appear to be genuinely raising incidence rates. Most epidemiologists now estimate that for every diagnosed case, two to five cases remain undetected.

The central culprit is gliadin, the alcohol-soluble fraction of gluten in wheat (analogous proteins exist in barley — hordein, and rye — secalin). Gliadin peptides, particularly the 33-mer alpha-gliadin sequence, are remarkably resistant to complete digestion by human gastrointestinal proteases. These partially digested fragments cross an already-permeable intestinal epithelium and enter the lamina propria, where the autoimmune cascade begins.

The Molecular Mechanism: How Gluten Destroys the Gut Lining

Understanding celiac pathophysiology at the molecular level is essential for interpreting diagnostic tests and explaining why strict dietary adherence is non-negotiable. The cascade has several distinct steps.

Step 1 — Deamidation by Tissue Transglutaminase 2

Once gliadin peptides cross the epithelial barrier, they encounter intestinal transglutaminase 2 (tTG2), an enzyme normally involved in tissue repair and cross-linking. tTG2 deamidates specific glutamine residues on gliadin peptides, converting them to glutamate. This single biochemical modification dramatically increases the affinity of gliadin peptides for HLA-DQ2 and HLA-DQ8 molecules — transforming a poorly immunogenic protein fragment into a potent antigen.

Step 2 — Antigen Presentation and T Cell Activation

Deamidated gliadin peptides are taken up by antigen-presenting cells (APCs) — primarily dendritic cells and macrophages in the lamina propria — and loaded onto HLA-DQ2/DQ8 surface molecules. This complex is presented to CD4+ T helper cells, which are activated into Th1 and Th17 phenotypes. The resulting cytokine storm includes interferon-γ, IL-15, and tumor necrosis factor-α.

Step 3 — Innate Immune Amplification

IL-15 plays a particularly destructive role: it activates intraepithelial lymphocytes (IELs), which directly attack intestinal epithelial cells displaying stress signals. This innate immune arm amplifies the adaptive T cell response, driving progressive epithelial destruction even in the absence of full adaptive immunity.

Step 4 — Villous Atrophy and Malabsorption

The combined effect of cytokine-driven inflammation, direct lymphocyte cytotoxicity, and crypt hyperplasia produces the hallmark lesion of celiac disease: villous atrophy. As intestinal villi flatten, the surface area available for nutrient absorption collapses — in Marsh 3c (total villous atrophy), absorptive surface is reduced by over 90%, resulting in profound malabsorption of fat-soluble vitamins, iron, calcium, zinc, folate, and B12.

Diagnosis: Serology, Biopsy, and the Gluten Challenge

The Antibody Toolkit

Celiac disease generates multiple measurable antibody responses. Each has distinct clinical utility:

• Anti-tTG2 IgA (tissue transglutaminase IgA): The primary screening test. ~95% sensitivity, ~95% specificity. Cost-effective, widely available, correlates with degree of mucosal damage. The test of choice for initial evaluation.
• Anti-endomysial IgA (EMA-IgA): The most specific celiac antibody. ~98% specificity, but lower sensitivity (~90%) and significantly more expensive and technically demanding (immunofluorescence on monkey esophagus or umbilical cord). Used to confirm equivocal tTG results.
• Anti-deamidated gliadin peptide IgG (DGP-IgG): Critical for patients with IgA deficiency, where tTG-IgA and EMA-IgA will be falsely negative. DGP-IgG offers ~80% sensitivity and ~98% specificity regardless of IgA status.
• Total serum IgA: Must always be checked simultaneously with tTG-IgA. IgA deficiency (defined as total IgA <7 mg/dL) is approximately 10 times more common in celiac patients than in the general population. Failure to check total IgA before relying on tTG-IgA is a diagnostic error that allows celiac disease to go undetected.

Small Bowel Biopsy — The Gold Standard

Positive serology must be confirmed by endoscopic small bowel biopsy in most cases. Guidelines recommend a minimum of 4 biopsy samples from the second portion of the duodenum (D2) and 2 samples from the duodenal bulb (D1), as mucosal damage is patchy. Samples are graded using the Marsh-Oberhuber classification.

The Gluten Challenge Requirement

This cannot be overstated: both celiac serology and small bowel biopsy require ongoing gluten consumption to be accurate. Testing a patient who is already on a gluten-free diet will produce false-negative serology and normalized or near-normal biopsy results, leading to misdiagnosis or delayed diagnosis.

The minimum requirement is 3 grams of gluten per day — approximately one to two regular slices of wheat bread — for a minimum of 6 consecutive weeks before serological testing, and for the same duration before endoscopy. Patients who cannot tolerate a gluten challenge should undergo HLA-DQ2/DQ8 typing: negative HLA typing effectively rules out celiac disease with >99% negative predictive value.

HLA Typing — The Rule-Out Test

HLA-DQ2/DQ8 typing is the most powerful tool for excluding celiac disease. If neither HLA-DQ2 nor HLA-DQ8 is present, celiac disease can be confidently excluded without requiring a gluten challenge or biopsy. This is particularly useful in patients who have already adopted a gluten-free diet before formal evaluation.

Clinical Presentation: Far Beyond Diarrhea

The textbook presentation of celiac disease — a malnourished child with explosive diarrhea, distended abdomen, and growth failure — represents only one end of a vast clinical spectrum. This "classic" presentation is increasingly uncommon in clinical practice, particularly in adults, and its dominance in medical education has led to profound under-diagnosis.

Classic Malabsorption Syndrome

Chronic diarrhea, steatorrhea (fatty, foul-smelling stools that float), significant weight loss, and failure to thrive in children remain the most recognizable presentation. These reflect the full consequences of Marsh 3c-level villous atrophy: inability to absorb fats, fat-soluble vitamins (A, D, E, K), and most micronutrients across large segments of the small bowel.

Atypical Presentation (Now the Majority in Adults)

In adults, constipation, bloating, and abdominal pain — an IBS-like picture — are now the most common presenting symptoms. Many of these patients carry IBS diagnoses for years before celiac testing is performed. Crucially, the absence of diarrhea should never be used to argue against celiac testing when other features suggest it.

Extra-Intestinal Manifestations

• Iron deficiency anemia: The single most common presenting symptom in adults, resulting from impaired iron absorption in the proximal small bowel. Often refractory to oral iron supplementation until the underlying celiac is treated.
• Osteoporosis and osteopenia: Secondary to calcium and vitamin D malabsorption. Significantly elevated fracture risk; DEXA scanning is standard at diagnosis and monitoring.
• Dermatitis herpetiformis (DH): The "skin form" of celiac disease — intensely pruritic, blistering rash symmetrically distributed on elbows, knees, buttocks, and scalp. Caused by IgA deposition in dermal papillae. tTG3 (epidermal transglutaminase) is the autoantigen. GFD is the only definitive treatment.
• Peripheral neuropathy: "Gluten neuropathy" — sensory predominant, often presenting as distal numbness and gait ataxia, attributable to direct neural autoimmunity and B12/vitamin E deficiency.
• Elevated liver enzymes (hypertransaminasemia): Present in up to 50% of celiac patients at diagnosis, normalizes with strict GFD in most cases. Mechanism involves gut permeability and portal translocation of antigens.
• Aphthous stomatitis: Recurrent oral ulcers linked to B12, folate, and zinc deficiency.
• Infertility and pregnancy loss: Undiagnosed celiac significantly increases miscarriage rates, intrauterine growth restriction, and time to conception in both men and women.

Silent/Asymptomatic Celiac

A significant subset of patients — identified through family screening or incidental serology — have positive antibodies and villous atrophy but report no symptoms. This "silent" celiac still carries the same long-term complication risks (osteoporosis, lymphoma, neuropathy, anemia) and still requires a strict gluten-free diet.

Celiac vs. NCGS vs. Wheat Allergy: The Diagnostic Triangle

Three distinct conditions produce symptoms following wheat or gluten ingestion, but their mechanisms, diagnostic markers, and long-term implications are fundamentally different. Confusing them leads to mismanagement.

The NCGS Debate: Is Gluten Even the Culprit?

Non-celiac gluten sensitivity is, by definition, a diagnosis of exclusion: symptoms mimicking celiac disease, with negative celiac serology, negative HLA typing, and normal or near-normal intestinal histology, following wheat or gluten ingestion. What has become increasingly controversial is whether gluten itself is the responsible agent.

A landmark 2013 re-analysis by Biesiekierski and colleagues — using rigorous double-blind, placebo-controlled rechallenge methodology — found that the majority of self-reported NCGS patients in their cohort showed no reproducible response to isolated gluten versus placebo. Instead, symptom induction was attributed to fructans, the FODMAP component of wheat (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols). Fructans are fermented rapidly by colonic bacteria, producing gas and osmotic effects that trigger IBS-like symptoms in susceptible individuals.

This does not mean NCGS is fictitious — it means the mechanism remains genuinely uncertain, and that many patients diagnosed with NCGS may benefit more from a low-FODMAP dietary approach than from strict gluten avoidance. The absence of long-term structural gut damage distinguishes NCGS from celiac and has significant implications for the degree of dietary restriction required.

Treatment, Monitoring, and the Hidden Pitfalls of the Gluten-Free Diet

The Gluten-Free Diet: Standard of Care and Non-Negotiable in Celiac

The strict, lifelong gluten-free diet (GFD) is the only established treatment for celiac disease. There are no FDA-approved medications, no supplements that compensate for gluten exposure, and no evidence that titrated tolerance develops with time. The Codex Alimentarius threshold for "gluten-free" labeling is <20 parts per million (ppm) of gluten — a standard that accounts for the smallest detectable immunologically relevant exposure.

Gluten-Containing Grains and Hidden Sources

The primary offenders are wheat (in all forms: spelt, kamut, durum, semolina, farro, einkorn), barley, and rye. Oats present a unique challenge: while oats themselves are gluten-free, they are almost universally contaminated through shared agricultural and processing equipment. Additionally, approximately 10–15% of celiac patients mount an immune response to avenin, the oat storage protein, even when consuming certified uncontaminated oats — making oat tolerance highly individual and requiring careful clinical assessment.

Hidden gluten sources that routinely cause ongoing exposure include: soy sauce (typically wheat-fermented), malt vinegar, beer, processed meats with fillers, shared fryers in restaurants, communion wafers, certain medications (excipients), and lip balms or cosmetics containing wheat germ.

The Nutritional Trap of Gluten-Free Products

Commercially produced gluten-free substitute foods — breads, pastas, crackers — are typically made from refined rice flour, tapioca starch, potato starch, or corn starch. These are not nutritionally equivalent to their wheat-based counterparts. They are typically lower in fiber, higher in glycemic index, lower in B vitamins, iron, and zinc, and often higher in fat and sugar to compensate for palatability. Transitioning to a GFD without active nutritional management frequently worsens pre-existing deficiencies.

Nutritional Deficiencies at Diagnosis — What Must Be Tested and Repleted

• Iron: Most commonly deficient; drives presenting anemia in adults. Requires aggressive repletion; IV iron is often necessary when GI absorption remains impaired.
• Vitamin D: Profoundly deficient in most celiac patients at diagnosis. Drives calcium malabsorption, secondary hyperparathyroidism, and bone loss. Requires high-dose supplementation (typically 2000–5000 IU/day) with monitoring.
• Calcium: Malabsorbed secondary to vitamin D deficiency and direct absorptive surface loss.
• B12: Deficient due to ileal involvement in some patients; relevant to neuropathy risk.
• Folate: Critical in women of childbearing age; malabsorption drives elevated homocysteine and neural tube risk.
• Zinc: Consistently depleted; affects immune function, taste, skin integrity.

Mucosal Healing Timelines

Initiating a strict GFD triggers histological recovery, but on a timeline that is often underappreciated by patients and clinicians:

• Children: Typically achieve full mucosal healing (Marsh 0–1) within 6–12 months of strict dietary adherence.
• Adults: Mucosal healing is significantly slower, requiring 18–24 months minimum on strict GFD, and often longer.
• Refractory celiac disease: Approximately 10–20% of adults maintain persistent villous atrophy despite documented strict GFD adherence. This is termed refractory celiac disease (RCD) and requires advanced workup including intraepithelial lymphocyte immunophenotyping to distinguish type I (normal IEL phenotype, better prognosis) from type II (aberrant IEL clones, associated with enteropathy-associated T cell lymphoma — EATL).

Monitoring Protocol on GFD

• tTG-IgA: annually (declining titers confirm dietary adherence and mucosal recovery)
• DEXA bone density scan: at diagnosis, then per osteoporosis guidelines
• Complete blood count, iron studies, B12, folate, vitamin D, zinc: at diagnosis and 6–12 months
• Repeat small bowel biopsy: typically at 18–24 months on GFD in adults to confirm mucosal healing, or sooner if symptoms persist

Frequently Asked Questions

Can I have celiac disease with a negative tTG-IgA?

Yes — and this is a clinically significant source of missed diagnoses. The most common reason for a false-negative tTG-IgA is IgA deficiency, which affects approximately 1 in 300 to 1 in 700 people in the general population but is 10 times more prevalent among celiac patients. When tTG-IgA returns negative, total serum IgA must always be checked. If IgA deficiency is confirmed, testing should shift to anti-deamidated gliadin peptide IgG (DGP-IgG) or IgG-class tTG. A false negative also occurs when the patient is already on a gluten-free diet at the time of testing.

Can celiac disease develop in adulthood?

Celiac disease can present at any age. While it is commonly diagnosed in early childhood, a significant proportion of new diagnoses occur in the third to fifth decades of life — and a growing number are diagnosed after age 60. Adults with new-onset celiac often have atypical presentations (anemia, neurological symptoms, elevated liver enzymes) rather than classic malabsorption, which delays diagnosis further. Genetic susceptibility is present from birth, but disease activation can be triggered at any point by physiological stress, infections, pregnancy, or other environmental factors.

Is non-celiac gluten sensitivity dangerous long-term?

Unlike celiac disease, NCGS has not been definitively linked to villous atrophy, intestinal lymphoma, osteoporosis, or the other long-term structural complications of celiac disease. However, because NCGS is still a poorly understood condition and long-term prospective data are limited, it would be premature to declare it entirely benign. The practical clinical approach is to confirm the diagnosis properly (rule out celiac with serology and, if needed, biopsy while on gluten), then manage symptoms pragmatically — often through a low-FODMAP approach or targeted wheat reduction rather than strict GFD.

What is dermatitis herpetiformis?

Dermatitis herpetiformis (DH) is considered the cutaneous manifestation of celiac disease. It presents as intensely itchy, blistering eruptions distributed symmetrically on extensor surfaces — elbows, knees, buttocks, and posterior scalp. Skin biopsy showing granular IgA deposition in dermal papillae is diagnostic. Approximately 10–15% of people with DH have symptomatic gastrointestinal celiac disease; the remainder have subclinical intestinal involvement detectable only on biopsy. The GFD is the cornerstone treatment — dapsone provides rapid symptom relief but does not treat the underlying gut pathology.